

## PRESS RELEASE

# Hansa Biopharma participating at LSX Nordic Congress

Lund, Sweden, 18 May. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled "Scaling Success: Key Drivers for Growing Nordic Biotechs" at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at [ir@hansabiopharma.com](mailto:ir@hansabiopharma.com).

**Event:** Panel Discussion at LSX Nordic Congress

**Title:** Scaling Success: Key Drivers for Growing Nordic Biotechs

**Date, Time, and Place:** Tuesday 19 May, 13:10 CET, Copenhagen, Denmark

**Moderator:** Søren Bregenholt, CEO at Alligator Biosciences

**Speakers:**

- Renée Aguiar-Lucander, CEO, Hansa Biopharma
- Hans Schambye, Chair / CEO, DANSK BIOTEK / BOOST Pharma
- Colleen Acosta, CEO & Co-Founder, Freya Biosciences
- Johanna Roostalu, Director, Human Health, Venture Creation, BII

--- ENDS ---

**Contacts for more information:**

Evan Ballantyne, Chief Financial Officer  
[IR@hansabiopharma.com](mailto:IR@hansabiopharma.com)

Kerstin Falck, VP Global Corporate Affairs  
[media@hansabiopharma.com](mailto:media@hansabiopharma.com)

**Notes to editors**

**About Hansa Biopharma**

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at [www.hansabiopharma.com](http://www.hansabiopharma.com) and follow us on [LinkedIn](#).

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.